Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Tango Therapeutics, Inc. due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Tango Therapeutics is expected to report a quarterly loss of $0.35 per share, reflecting a year-over-year change of -45.8% [3]. - Revenues are projected to be $6.19 million, down 68.9% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.62% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Tango Therapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.57% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Tango Therapeutics currently holds a Zacks Rank of 2, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Tango Therapeutics was expected to post a loss of $0.34 per share but actually reported a loss of -$0.36, resulting in a surprise of -5.88% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - Krystal Biotech, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $1.08 for the same quarter, indicating a year-over-year change of +25.6% [18]. - Revenues for Krystal Biotech are expected to be $90.5 million, up 28.8% from the previous year [18].